Literature DB >> 10711453

Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialadenitis: report of the overlapping of these two autoimmune diseases.

K Tsuneyama1, K Saito, B H Ruebner, I Konishi, Y Nakanuma, M E Gershwin.   

Abstract

Primary sclerosing cholangitis (PSC) is characterized by destructive inflammation and fibrosis affecting the bile ducts. The etiology of PSC is still unknown, although lymphocytic infiltration in the portal areas suggests an immune-mediated destruction of the bile ducts. Patients with one autoimmune disease often suffer from one or more other autoimmune diseases. It is well known that there is a close relationship between PSC and inflammatory bowel disease, particularly ulcerative colitis(UC). However, the pathological findings in UC and other overlap diseases do not resemble those of PSC. In the present study, we report a patient with chronic sclerosing sialadenitis (Kuttner's tumor) and PSC. It is compared the sclerosing changes in both salivary glands and bile ducts histologically. In addition, the expression pattern of mast cell tryptase, b-FGF, and HLA-DR were examined in both tissues immunohistochemically. Histological features of sclerosing change in both salivary and bile ducts were quite similar. Marked mast cell infiltration and b-FGF expression were seen in the sclerosing areas in both tissues. In active inflammatory areas of the salivary glands, HLA-DR expression was also seen. We hypothesized that similar immune reactions occur in both the salivary gland and bile ducts and are responsible for the fibrosis that follows.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711453     DOI: 10.1023/a:1005429130150

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  Role of immune factors in the pathogenesis of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Semin Liver Dis       Date:  1991-02       Impact factor: 6.115

2.  Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium.

Authors:  A Mandal; A Dasgupta; L Jeffers; L Squillante; S Hyder; R Reddy; E Schiff; K M Das
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

3.  Primary sclerosing cholangitis.

Authors:  E R Dickson; N F LaRusso; R H Wiesner
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

4.  Histological features of sclerosing cholangitis in patients with chronic ulcerative colitis.

Authors:  C Barbatis; P Grases; H A Shepherd; R W Chapman; J Trowell; D P Jewell; J O McGee
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

5.  Hepatic mucosal mast cell hyperplasia in rats with secondary biliary cirrhosis.

Authors:  K P Rioux; K A Sharkey; J L Wallace; M G Swain
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

6.  Intrahepatic mast cells in chronic liver diseases.

Authors:  D J Farrell; J E Hines; A F Walls; P J Kelly; M K Bennett; A D Burt
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

7.  Current concepts. Primary sclerosing cholangitis.

Authors:  N F LaRusso; R H Wiesner; J Ludwig; R L MacCarty
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

8.  Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjögren's syndrome.

Authors:  K Tsuneyama; J Van de Water; Y Nakanuma; S Cha; A Ansari; R Coppel; M E Gershwin
Journal:  Hepatology       Date:  1994-10       Impact factor: 17.425

9.  Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis.

Authors:  R H Wiesner; N F LaRusso; J Ludwig; E R Dickson
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

10.  Tumour-like lesions of the salivary glands. The new WHO classification.

Authors:  G Seifert
Journal:  Pathol Res Pract       Date:  1992-10       Impact factor: 3.250

View more
  9 in total

1.  Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Authors:  Hannah Jones; Laura Hargrove; Lindsey Kennedy; Fanyin Meng; Allyson Graf-Eaton; Jennifer Owens; Gianfranco Alpini; Christopher Johnson; Francesca Bernuzzi; Jennifer Demieville; Sharon DeMorrow; Pietro Invernizzi; Heather Francis
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

Review 2.  The emerging role of mast cells in liver disease.

Authors:  Veronica Jarido; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Kristen Stephenson; Heather Francis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-04       Impact factor: 4.052

3.  Unusual involvement of IgG4-related sclerosing disease in lacrimal and submandibular glands and extraocular muscles.

Authors:  Yong Un Shin; Young-Ha Oh; Yoon Jung Lee
Journal:  Korean J Ophthalmol       Date:  2012-05-22

Review 4.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

5.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis in a Pediatric Patient With Neurofibromatosis Type 1.

Authors:  Emily Lehan; Tao Wang; Don Soboleski; Amy Acker; Mohit Kehar
Journal:  ACG Case Rep J       Date:  2021-05-14

Review 6.  Hyper-IgG4 disease: report and characterisation of a new disease.

Authors:  Guy H Neild; Manuel Rodriguez-Justo; Catherine Wall; John O Connolly
Journal:  BMC Med       Date:  2006-10-06       Impact factor: 8.775

Review 7.  Aging-Related Molecular Pathways in Chronic Cholestatic Conditions.

Authors:  Claudio Pinto; Elisabetta Ninfole; Antonio Benedetti; Luca Maroni; Marco Marzioni
Journal:  Front Med (Lausanne)       Date:  2020-01-21

8.  Mast cells and the liver aging process.

Authors:  Fabio Grizzi; Maurizio Chiriva-Internati; Giuseppe Di Caro; Luigi Laghi; Paul Hermonat; Paolo Mazzola; Diane D Nguyen; Saba Radhi; Jose A Figueroa; Everardo Cobos; Giorgio Annoni
Journal:  Immun Ageing       Date:  2013-03-07       Impact factor: 6.400

9.  Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch.

Authors:  Fangmei An; Sumitaka Yamanaka; Sarah Allen; Lewis R Roberts; Gregory J Gores; Timothy M Pawlik; Qing Xie; Masaharu Ishida; Esteban Mezey; Anne C Ferguson-Smith; Yuriko Mori; Florin M Selaru
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.